@article{ajcmr2016412,
author={{I.I., Komkova and P.E., Tkachenko and M.V., Maevskaya and V.T., Ivashkin},
title={Budesonide in Severe Alcoholic Hepatitis: Results of the Original Research},
journal={American Journal of Clinical Medicine Research},
volume={4},
number={1},
pages={7--10},
year={2016},
url={http://pubs.sciepub.com/ajcmr/4/1/2},
issn={2328-403X},
abstract={<b>Background and aim</b>: Severe alcoholic hepatitis (AH) is a life-threatening alcoholic liver disease with a potential of 30-40% mortality at 1 month. While steroids remain to be a first line therapy, there is a need in alternative treatment. The aim of the study is to compare efficacy and safety of budesonide and prednisolone in treatment of severe AH and to determine predictors of none-response, predictors of short-term mortality. <b>Methods:</b> 37 patients with severe AH were randomized in 2 groups and enrolled in the prospective trial. Group 1 (n=17) patients received budesonide 9 mg/daily per os, group 2 (n=20) patients were managed with prednisolone 40 mg/daily per os. Treatment duration was 28 days. Response criteria 每 Lille model. <b>Results</b><b>:</b> There were no significant differences in short-term survival (把 = 0,857). In group 2 adverse events were statistically more frequently than in group 1 (70% vs. 26,7%, 把 = 0,011). Hepatorenal syndrome occurred more frequently in group 2 (把 = 0,033). Predictors of non-response were MELD score (把 = 0,009), ABIC score (把 = 0,011), hepatic encephalopathy (p=0,035), total bilirubin (p=0,016). Predictors of mortality were Lille score (p=0,018), serum glucose (p=0,017), total bilirubin level at the 7th day of the therapy (p=0,030). <b>Conclusions:</b> Budesonide therapy for patients with severe alcoholic hepatitis showed same efficacy as prednisolone treatment with significantly less adverse events. Budesonide appears to be effective in prevention of hepatorenal syndrome.},
doi={10.12691/ajcmr-4-1-2}
publisher={Science and Education Publishing}
}